Investigational drug · Phase 2
RC88
Also called: The RC88
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Solid Tumor, Advanced Solid Tumours, Primary Peritoneal Cancer.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
3
0 still active
All registered trials
5
Any phase or sponsor naming "RC88"
First trial start
2020
Apr 14, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RC88", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
- Advanced Solid Tumours
- Primary Peritoneal Cancer
- Fallopian Tube Cancer
- Epithelial Ovarian Cancer
Approved drugs for the same conditions: Ovarian cancer · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "RC88" as an intervention, largest first.
RemeGen Co., Ltd.Industry
NCT06016062 · 221 participants (planned) · Start Sep 14, 2023 · Primary completion Dec 31, 2025
Drug: RC148 Monotherapy; RC148+docetaxel Combination Therapy and 3 more · For: Solid Tumor
Sites: Anhui, China; Beijing, China; Changchun, China · 31 sites in all
RemeGen Co., Ltd.Industry
NCT04175847 · 198 participants · Start Apr 14, 2020 · Primary completion Dec 31, 2025
Drug: RC88 · For: Solid Tumor
Sites: Beijing, China; Zhengzhou, China; Nanjing, China · 4 sites in all
RemeGen Co., Ltd.Industry
NCT05804526 · 82 participants (planned) · Start Jul 19, 2023 · Primary completion May 2025
Drug: RC88; Sintilimab Injection · For: Advanced Solid Tumours
Sites: Beijing, China
RemeGen Co., Ltd.Industry
NCT06173037 · 43 participants · Start Jan 19, 2024 · Primary completion Dec 31, 2025
Drug: RC88 · For: Primary Peritoneal Cancer; Fallopian Tube Cancer; Epithelial Ovarian Cancer
Sites: Hefei, China; Beijing, China; Chongqing, China · 30 sites in all
- A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid TumoursCompleted
RemeGen Co., Ltd.Industry
NCT05508334 · 41 participants · Start Jan 30, 2023 · Primary completion Nov 26, 2025
Drug: RC88 · For: Advanced Solid Tumours
Sites: Beijing, China · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Conformational epitope engagement by anti-MSLN ADC RC88 confers resistance to soluble mesothelin.
Xu Y, Li M, Wang L, et al. · Antib Ther 2026
- Therapeutic Applications and Target Strategies of Antibody-Drug Conjugates in Ovarian Cancer.
Liu Q, Zhou R, He T, et al. · Iran J Pharm Res 2025
- Translation of the efficacy of antibody-drug conjugates from preclinical to clinical using a semimechanistic PK/PD model: A case study with RC88.
Li Q, Wang L, Zhang J, et al. · Clin Transl Sci 2023
- Preclinical safety profile of RC88-ADC:a novel mesothelin-targeted antibody conjugated with Monomethyl auristatin E.
Jiang J, Li S, Tang N, et al. · Drug Chem Toxicol 2023
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.